drugset / Trial / NCT02597907

Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant

NCT02597907

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study was to compare the antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in high risk patients undergoing laparoscopic cholecystectomy.

Timeline

Start
2014-07
Primary completion
2015-05
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Palonosetron Other / unclassified 0.075 mg
Comparator Ramosetron Small molecule 0.3 mg
Background Aprepitant Other / unclassified 80 mg

Indications

No indication recorded.